|
| 37348074 | Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients. | Ther Drug Monit | 2024 |
| 37906253 | Are novel oral oncolytics underdosed in obese patients? | Cancer Chemother Pharmacol | 2024 |
| 37939124 | Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. | Clin Cancer Res | 2024 |
| 37982822 | Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. | Clin Cancer Res | 2024 |
| 36282874 | Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. | Clin Cancer Res | 2023 |
| 37598656 | Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. | Eur J Cancer | 2023 |
| 37597246 | Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. | Oncologist | 2023 |
| 37856077 | The association of having a monitoring or blunting coping style with psychological distress, health-related quality of life and satisfaction with healthcare in gastrointestinal stromal tumour (GIST) patients. | Acta Oncol | 2023 |
| 37902257 | Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators. | Cancer Med | 2023 |
| 37584840 | Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. | Clin Pharmacokinet | 2023 |
| 37828717 | The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib. | Clin Transl Sci | 2023 |
| 37686693 | Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling. | Cancers (Basel) | 2023 |
| 37814179 | Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients. | Ann Surg Oncol | 2023 |
| 37125403 | Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. | EClinicalMedicine | 2023 |
| 36947208 | Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients. | Cancer Chemother Pharmacol | 2023 |
| 36944815 | Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer. | Pharm Res | 2023 |
| 37246093 | Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry. | Eur J Surg Oncol | 2023 |
| 37079223 | Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. | Target Oncol | 2023 |
| 37444404 | Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges. | Cancers (Basel) | 2023 |
| 37310647 | CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients. | Clin Pharmacokinet | 2023 |
| 37173151 | Elevated preoperative serum interleukin-6 level is predictive for worse postoperative outcome after soft tissue sarcoma surgery. | Eur J Surg Oncol | 2023 |
| 37172331 | Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients. | Biomed Pharmacother | 2023 |
| 37236033 | WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study. | Gynecol Oncol | 2023 |
| 36969063 | Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC). | Front Oncol | 2023 |
| 37194167 | Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function. | Br J Clin Pharmacol | 2023 |
| 37062209 | Local recurrence in primary localised resected gastrointestinal stromal tumours:Â A registry observational national cohort study including 912 patients. | Eur J Cancer | 2023 |
| 36409435 | A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors. | Invest New Drugs | 2023 |
| 36621142 | Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors. | Biomed Pharmacother | 2023 |
| 36689692 | Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. | J Clin Oncol | 2023 |
| 36893690 | Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review. | Cancer Treat Rev | 2023 |
| 34727226 | Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. | Support Care Cancer | 2022 |
| 35775126 | Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer. | Clin Transl Sci | 2022 |
| 35653981 | Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. | ESMO Open | 2022 |
| 35352280 | Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. | Pharm Res | 2022 |
| 35406604 | Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. | Cancers (Basel) | 2022 |
| 35834987 | Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer. | Biomed Pharmacother | 2022 |
| 35397932 | Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management. | Semin Oncol | 2022 |
| 35426526 | Is age just a number? A population pharmacokinetic study of gemcitabine. | Cancer Chemother Pharmacol | 2022 |
| 35777707 | Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. | Ann Oncol | 2022 |
| 36520526 | Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study. | JMIR Form Res | 2022 |
| 36463731 | Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. | ESMO Open | 2022 |
| 36493601 | Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? | ESMO Open | 2022 |
| 36481665 | Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. | Nat Commun | 2022 |
| 36374447 | Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients. | Target Oncol | 2022 |
| 36097345 | Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid AÂ analog development. | Clin Transl Sci | 2022 |
| 36055309 | The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. | Lancet Oncol | 2022 |
| 36055228 | Detection and localization of early- and late-stage cancers using platelet RNA. | Cancer Cell | 2022 |
| 35980618 | Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). | JAMA Oncol | 2022 |
| 35978149 | Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting. | Pharm Res | 2022 |
| 36185303 | Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? | Front Oncol | 2022 |